The levels of insulin and C-peptide in the treatment group were increased significantly either(P<0.01),and the increasement was more significant compared with that of diabetes non-treatment group(P<0.05).
Methods:Diabetic rats were induced by streptozocin(STZ) and divided into 2 groups,each group 20 rats,one group without treatment; the other group treated with tetromethylpragine, and 20 normal rats used as control group. At the 4 th week and 12 th week,body weight,blood sugar,retina SOD activity and MDA content were examined.
Methods The diabetic rat model was developed by intraperitoneal injection of streptozocin. The cardiovascular diseases in normal control group (A),insulin-treated diabetic group (B),and diabetic group without treatment (C) were observed by immunohistochemical and electromicroscopic methods.
Following hydralazine therapy systolic wall stress was even lower (140±26.5·103 dyn/cm2) in comparison to the untreated group (171±26.0·103 dyn/cm3, p>amp;lt;0.05).
Post-ischemic functional recovery was significantly improved by in vivo administration of CP 205, by perfusion with 5 μg/ml of EGb 761 or with both terpenoids as compared to untreated group but in vitro CP 205 was not effective.
However, this resulted in a significant reduction of stenosis degree of 66 % 8 weeks after intervention compared to the untreated group (untreated 41 ± 18 % vs paclitaxel treated 14 ± 11 %, p = 0.005).
Twenty-four h after permanent occlusion of the middle cerebral artery (MCA) in the cat, the hemispheric swelling due to edema is markedly reduced under treatment with large doses of dexamethasone than is the case with the untreated group.
The potassium content of the non-ischemic tissue is slightly increased in the dexamethasone treated animals when comparing with the untreated group.
As for the ERCC1 8092 C/A, no significant effects were observed in the treated group and the non-treatment group.
But the percentage of bone mineral density decrease was found to be significantly lower in the treatment group than in the non-treatment group (4.6±2.1% vs.
The remaining 10169 women were the 'non-treatment group'.
Fractures in the non-treatment group occurred at a rate of 39.8 fractures/10000 person-years.
We evaluated with zymogram, reverse zymogram, and cell invasion assay after exposure of SI-27 for 24?h followed by preliminary MTT assay to find non-cytotoxic dose range, 5?10?50?100?μg/ml compared with non-treatment group as the control.
There were no treatment group differences in the binding of [3H]-spiperone or [3H]-leuenkephalin to rat striatal membranes.
The group of mice treated with the combination of CC-36-FL+IL-2 showed a significant reduction in tumor burden when compared to the no treatment group and the other control treatment groups (P>amp;lt;0.05).
Insulin-like growth factor 1 levels measured in the MCF-7 tumors significantly decreased in the TAT-59 alone group and in the no treatment group as compared with the E2 alone group.
Six rabbits underwent caesarean section on gestational day 31 for fetal harvest; three of them had no treatment (group T) and three received corticosteroid treatment (group TC).
The other six rabbits underwent caesarean section on gestational day 29 for fetal harvest (preterm delivery); three of them had no treatment (group P) and three received corticosteroid treatment (group PC).
In a control group without treatment the mortality was 63% 80 h after infection.
Group 1 (n=7) was the nonischemic control group without treatment; Group 2 (n=6) was the ischemic control group treated with physiologic solution; Group 3 (n=5) received TMZ; Group 4 (n=5) received Se; and Group 5 (n=6) received TMZ+Se for 15 days.